4.7 Article

Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 20, Issue 2, Pages 438-446

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2021.01.026

Keywords

Health-Related Quality Of Life; Viral Hepatitis; Direct-Acting Antiviral; HRQL; Viral Clearance

Ask authors/readers for more resources

Achieving sustained virologic response improves patient reported outcomes in patients with HCV cirrhosis. Patients with compensated cirrhosis have severe impairment in baseline PROs, but show significant improvement after achieving SVR. Patients with decompensated cirrhosis also experience improvement in PROs, but there is a declining trend after 2 years.
BACKGROUND & AIMS: Achieving sustained virologic response (SVR) among patients with hepatitis C virus (HCV) leads to patient reported outcome (PRO) improvement. We aimed to assess the long-term post-SVR PRO trends in HCV patients with cirrhosis. METHODS: Patients with HCV and cirrhosis treated in clinical trials with direct acting antiviral agents (DAAs) who achieved SVR-12 were prospectively enrolled in a long-term registry (clinicaltrials.gov #NCT02292706). PROs were collected every 24 weeks using the Short Form-36v2 (SF-36), CLDQ-HCV, and WPAI-HCV. RESULTS: Pre-treatment baseline data were available for 854 cirrhotic patients who achieved SVR after DAAs. Of these, 730 had compensated (CC) and 124 had decompensated cirrhosis (DCC) before treatment- patients with DCC reported severe impairment in their PROs in comparison to CC patients (by mean -5% to -16% of a PRO range size; p < .05 for 16 out of 20 studied PROs]. After achieving SVR and registry enrollment, significant PRO improvements were noted from pretreatment levels in 11/20 domains for those with DCC (+4% to + 21%) and 19/20 PRO domains in patients with CC (+3% to + 17%). Patients with baseline DCC had higher rates of hepatocellular carcinoma and mortality (P < .05). In patients with CC, the PRO gains persisted up to 168 weeks (3.5 years) of registry follow-up. In patients with DCC, the improvements lasted for at least 96 weeks but a declining trend after year 2. CONCLUSIONS: Patients with HCV cirrhosis experience severe PRO impairment at baseline with sustainable improvement after SVR. Though those with DCC experience improvement, there is a decline after 2 years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available